TABLE 3.

Key ongoing clinical trials of cell therapies for spinal cord injury

Cell type	Sponsor; country	Phase; Clinicaltrials.gov identifier; study status	Estimated enrollment; age	Injury level; severity; transplant interval after SCI	Route of cell delivery	Estimated completion date
Autologous MSC	Hospital Sao Rafael, Brazil	Phase I; NCT02574572; recruiting	10; 18‐65 yr	C5‐C7; ASIA A; more than 12 mo	Intraspinal	Jun 2020
Autologous MSC	Hospital Sao Rafael, Brazil	Phase II; NCT02574585; not yet recruiting	40; 18‐65 yr	T1‐L2; ASIA A; more than 12 mo	Percutaneous; 2 injections 3 mo apart	Jan 2022
Autologous MSC	Pharmicell Co., Ltd., Seoul, Korea	Phase II/III; NCT01676441; active, not recruiting	32; 16‐65 yr	Cervical; ASIA B; more than 12 mo	Intraspinal and intrathecal	Dec 2020
Autologous Adipose‐derived MSC	Allan Dietz, Mayo Clinic, United States	Phase I; NCT03308565; recruiting	10; 18 yr and older	AISA A‐B; 2 wk to 1 yr	Intrathecal; single injection	Nov 2023
Autologous BM‐MNC	Da Nang Hospital, Vietnam	Phase I/II; NCT02923817; recruiting	30; 20‐60 yr	ASIA A‐B; 3 wk to 12 mo	Intrathecal	Jun 2019 a
Allogeneic UC‐derived MSC	The Third Affiliated Hospital, Sun Yat‐Sen University, Guangdong, China	Phase I/II; NCT03505034; recruiting	43; 18‐65 yr	ASIA A‐D; more than 12 mo	Intrathecal	Dec 2021
Allogeneic UC‐derived MSC	Limin Rong, Third Affiliated Hospital, Sun Yat‐Sen University, Guangdong, China	Phase I/II; NCT02481440; recruiting	44; 18‐65 yr	ASIA A‐D; more than 2 wk	Intrathecal; monthly injections for 4 mo	Dec 2018 a
Allogeneic UC‐derived MSC	The Third Affiliated Hospital, Sun Yat‐Sen University, Guangdong, China	Phase II; NCT03521323; recruiting	92; 18‐65 yr	ASIA A‐D; 2‐12 mo	Intrathecal; monthly injections for 4 mo	Dec 2022
Allogeneic UC‐derived MSC	The Third Affiliated Hospital, Sun Yat‐Sen University, Guangdong, China	Phase II; NCT03521336; recruiting	130; 18‐65 yr	ASIA A‐D; subacute (2 wk to 2 mo), early chronic (2‐12 mo), chronic (more than 12 mo)	Intrathecal; monthly injections for 4 mo	Dec 2022
Allogeneic WJ‐derived MSC	Banc de Sang i Teixits, Barcelona, Spain	Phase I/II; NCT03003364; active, not recruiting	10; 18‐65 yr	T2‐T11; ASIA A; 1‐5 yr	Intrathecal	Apr 2020
Human Spinal Cord‐derived NSC	Neuralstem Inc, United States	Phase I; NCT01772810; recruiting	8; 18‐65 yr	T2‐T12 or C5‐C7; ASIA A; 1‐2 yr	Intraspinal	Dec 2022
Autologous OEC	Wroclaw Medical University, Poland	Phase I; NCT01231893; unknown status	10; 16‐65 yr	C5‐L5; ASIA A; Interval N/A	Intraspinal	N/A a

Note: Clinical trials currently recruiting or ongoing are identified with the NCT number listed on www.ClinicalTrials.gov.

Abbreviations: BM‐MNC, bone marrow‐derived mononuclear cells; BMSC, bone marrow‐derived mesenchymal stem cells; ESC, embryonic stem cell; MSC, mesenchymal stem cells; NSPC, neural stem/progenitor cells; OEC, olfactory ensheathing cells; OPC, oligodendrocyte precursor cells; UC‐derived MSC, umbilical cord‐derived mesenchymal stem cells; WJ‐derived MSC, Wharton's jelly‐derived mesenchymal stem cells.

^aStatus unknown or not updated on clinicaltrials.gov.